{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:49:12Z","timestamp":1782460152646,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rebound of coronavirus disease 2019 (COVID-19) is defined as return of symptoms and\/or viral positivity after resolution of the initial infection. While rebound is typically mildly symptomatic and rarely associated with progression to severe disease, the benefit of repeated antiviral treatment has not been investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of a second 5-day treatment course of nirmatrelvir\/ritonavir versus placebo\/ritonavir in participants with symptomatic mild to moderate COVID-19 with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapid antigen test within 14 days of initial nirmatrelvir\/ritonavir treatment. The primary efficacy endpoint was the change in viral SARS-CoV-2 RNA level from baseline to Day 5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The full analysis set included 436 participants assigned to treatment (292, nirmatrelvir\/ritonavir; 144, placebo\/ritonavir). A second 5-day course of nirmatrelvir\/ritonavir resulted in a significant reduction in viral RNA levels at Day 5 compared with placebo\/ritonavir (P = .0004; 95% CI, \u22121.09, \u2212.32). The median time to 2 consecutive negative RAT results was 4 versus 5 days, and the median time to sustained alleviation of all targeted signs\/symptoms was 8 versus 9 days in the nirmatrelvir\/ritonavir and placebo\/ritonavir groups, respectively. Retreatment with nirmatrelvir\/ritonavir was safe and well tolerated, and there were no occurrences of COVID-19\u2013related hospitalizations or deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A repeated 5-day course of nirmatrelvir\/ritonavir was safe and well tolerated and was associated with a faster decline in viral RNA levels. In this study, there was no clear benefit of retreatment because rebound was transient and mild and did not lead to severe COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT05567952; https:\/\/clinicaltrials.gov\/study\/NCT05567952.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf548","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:53:13Z","timestamp":1758973993000},"page":"e33-e40","source":"Crossref","is-referenced-by-count":1,"title":["Retreatment With Nirmatrelvir\/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity"],"prefix":"10.1093","volume":"82","author":[{"given":"Wuyan","family":"Zhang","sequence":"first","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Lake Forest, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Terra","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Groton, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Alan","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Bramson","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Leister-Tebbe","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Baniecki","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Guan","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Agyemang","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Ltd , Tadworth ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Italia srl , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Wisemandle","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Lake Forest, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-8558","authenticated-orcid":false,"given":"Jennifer","family":"Hammond","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development, Pfizer Inc , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2026020904075197700_ciaf548-B1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026020904075197700_ciaf548-B2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"2026020904075197700_ciaf548-B3","volume-title":"Paxlovid (nirmatrelvir tablets; ritonavir tablets)","year":"2025"},{"key":"2026020904075197700_ciaf548-B4","author":"Centers for Disease Control and Prevention"},{"key":"2026020904075197700_ciaf548-B5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.15585\/mmwr.mm7251a1","article-title":"SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals","volume":"72","author":"Smith","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026020904075197700_ciaf548-B6"},{"key":"2026020904075197700_ciaf548-B7","doi-asserted-by":"crossref","first-page":"e0162324","DOI":"10.1128\/jvi.01623-24","article-title":"Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance","volume":"99","author":"Phan","year":"2025","journal-title":"J Virol"},{"key":"2026020904075197700_ciaf548-B8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.7326\/M22-2381","article-title":"Symptom and viral rebound in untreated SARS-CoV-2 infection","volume":"176","author":"Deo","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026020904075197700_ciaf548-B9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026020904075197700_ciaf548-B10","doi-asserted-by":"crossref","first-page":"ofae243","DOI":"10.1093\/ofid\/ofae243","article-title":"Viral SARS-CoV-2 rebound rates in linked commercial pharmacy-based testing and health care claims","volume":"11","author":"Kelly","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026020904075197700_ciaf548-B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciad102","article-title":"The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls","volume":"77","author":"Pandit","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026020904075197700_ciaf548-B12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/cid\/ciad696","article-title":"Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir\/ritonavir compared with propensity score-matched untreated individuals","volume":"78","author":"Smith-Jeffcoat","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020904075197700_ciaf548-B13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(22)00873-8","article-title":"Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study","volume":"23","author":"Wong","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026020904075197700_ciaf548-B14","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/cid\/ciac481","article-title":"Rebound phenomenon after nirmatrelvir\/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons","volume":"76","author":"Ranganath","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026020904075197700_ciaf548-B15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s12879-024-09842-8","article-title":"Clinical rebound after treatment with nirmatrelvir\/ritonavir in COVID-19","volume":"24","author":"Camp","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026020904075197700_ciaf548-B16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.15585\/mmwr.mm7251a2","article-title":"Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir\/ritonavir treatment in randomized, double-blind, placebo-controlled trials\u2014United States and international sites, 2021\u20132022","volume":"72","author":"Harrington","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026020904075197700_ciaf548-B17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"Nirmatrelvir-ritonavir and viral load rebound in Covid-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026020904075197700_ciaf548-B18","doi-asserted-by":"crossref","first-page":"eadl4013","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci Adv"},{"key":"2026020904075197700_ciaf548-B19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2026020904075197700_ciaf548-B20","author":"Division of AIDS"},{"key":"2026020904075197700_ciaf548-B21","author":"Baniecki"},{"key":"2026020904075197700_ciaf548-B22","doi-asserted-by":"crossref","first-page":"105819","DOI":"10.1016\/j.ebiom.2025.105819","article-title":"Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19","volume":"118","author":"Hammond","year":"2025","journal-title":"eBioMedicine"},{"key":"2026020904075197700_ciaf548-B23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa2309002","article-title":"Oral nirmatrelvir-ritonavir as postexposure prophylaxis for Covid-19","volume":"391","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020904075197700_ciaf548-B24","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir\/ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a randomized, double-blind, phase 2 trial","author":"Weinstein","year":"2025","journal-title":"Lancet Inf Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf548\/64455663\/ciaf548.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e33\/64455663\/ciaf548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e33\/64455663\/ciaf548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:08:02Z","timestamp":1770628082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/e33\/8269311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf548","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,9,30]]}}}